2025
M12 Contingency Management With Stepped Care for Unhealthy Alcohol Use Among Individuals With HIV: Initial Findings From a Multisite Randomized Controlled Trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Brown S, Ferguson T, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. M12 Contingency Management With Stepped Care for Unhealthy Alcohol Use Among Individuals With HIV: Initial Findings From a Multisite Randomized Controlled Trial. Drug And Alcohol Dependence 2025, 267: 111606. DOI: 10.1016/j.drugalcdep.2024.111606.Peer-Reviewed Original ResearchIntegrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Integrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2025, 98: 72-81. PMID: 39321757, DOI: 10.1097/qai.0000000000003534.Peer-Reviewed Original ResearchUnhealthy alcohol useSelf-reported abstinenceAlcohol useLost to follow-upContingency managementAlcohol use disorderRandomized controlled trialsSubstance use treatmentAlcohol abstinenceFollow-upUse disorderControlled trialsPWHAlcohol treatmentAbstinenceUse treatmentEvidence of abstinenceHIVWeeksMean proportionTreatmentTrialsAlcoholDaysParticipants
2024
W80 Buprenorphine-Naloxone vs. Extended-Release Naltrexone for Opioid Use Disorder in People With Recent Criminal Legal Involvement: A Secondary Analysis of the X:BOT Randomized Controlled Trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. W80 Buprenorphine-Naloxone vs. Extended-Release Naltrexone for Opioid Use Disorder in People With Recent Criminal Legal Involvement: A Secondary Analysis of the X:BOT Randomized Controlled Trial. Drug And Alcohol Dependence 2024, 260: 110698. DOI: 10.1016/j.drugalcdep.2023.110698.Peer-Reviewed Original ResearchBuprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply